| 50.88 -0.23 (-0.45%) | 02-20 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 61.35 | 1-year : | 63.99 |
| Resists | First : | 52.53 | Second : | 54.79 |
| Pivot price | 50.9 |
|||
| Supports | First : | 48.88 | Second : | 40.66 |
| MAs | MA(5) : | 50.54  |
MA(20) : | 51.3 |
| MA(100) : | 47.8 |
MA(250) : | 37.88 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45.8 |
D(3) : | 39.8 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 54.79 | Low : | 22.32 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SBIO ] has closed above bottom band by 49.2%. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 51.09 - 51.36 | 51.36 - 51.56 |
| Low: | 49.9 - 50.17 | 50.17 - 50.39 |
| Close: | 50.44 - 50.91 | 50.91 - 51.26 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Thu, 19 Feb 2026
This Biotech ETF Is a Catalyst-Rich Story - ETF Trends
Sun, 15 Feb 2026
(SBIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Wed, 04 Feb 2026
(SBIO) Risk Channels and Responsive Allocation - Stock Traders Daily
Thu, 29 Jan 2026
Biotech M&A Wave Positions SBIO for Growth - ETF Database
Tue, 06 Jan 2026
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026? - Nasdaq
Wed, 24 Dec 2025
ALPS ETFs in Biotech and Commodities Lead 2025 Gains - ETF Database
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|